Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of ARS 220.26 trillion. The enterprise value is 241.05 trillion.

Market Cap	220.26T
Enterprise Value	241.05T

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Sep 15, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.30%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 19.82 and the forward PE ratio is 14.77.

PE Ratio	19.82
Forward PE	14.77
PS Ratio	5.53
PB Ratio	7.49
P/TBV Ratio	n/a
P/FCF Ratio	17.54
P/OCF Ratio	16.62
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.64, with an EV/FCF ratio of 19.20.

EV / Earnings	21.69
EV / Sales	5.72
EV / EBITDA	11.64
EV / EBIT	14.64
EV / FCF	19.20

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 16.14%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	16.14%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	2.26B
Profits Per Employee	631.52M
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 2.43 trillion in taxes.

Income Tax	2.43T
Effective Tax Rate	17.96%

Stock Price Statistics

The stock price has increased by +85.24% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+85.24%
50-Day Moving Average	45,216.00
200-Day Moving Average	37,489.25
Relative Strength Index (RSI)	47.33
Average Volume (20 Days)	260

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.31

Income Statement

In the last 12 months, Gilead Sciences had revenue of ARS 39.86 trillion and earned 11.11 trillion in profits. Earnings per share was 8,802.50.

Revenue	39.86T
Gross Profit	31.38T
Operating Income	15.58T
Pretax Income	13.55T
Net Income	11.11T
EBITDA	19.37T
EBIT	15.58T
Earnings Per Share (EPS)	8,802.50

Full Income Statement

Balance Sheet

The company has 11.64 trillion in cash and 34.18 trillion in debt, giving a net cash position of -19,798.24 billion.

Cash & Cash Equivalents	11.64T
Total Debt	34.18T
Net Cash	-19,798.24B
Net Cash Per Share	n/a
Equity (Book Value)	29.41T
Book Value Per Share	23,768.57
Working Capital	7.64T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 13.25 trillion and capital expenditures -692.10 billion, giving a free cash flow of 12.56 trillion.

Operating Cash Flow	13.25T
Capital Expenditures	-692.10B
Free Cash Flow	12.56T
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

This stock pays an annual dividend of 585.78, which amounts to a dividend yield of 1.25%.

Dividend Per Share	585.78
Dividend Yield	1.25%
Dividend Growth (YoY)	37.90%
Years of Dividend Growth	6
Payout Ratio	6.65%
Buyback Yield	-1.02%
Shareholder Yield	0.23%
Earnings Yield	5.05%
FCF Yield	5.70%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7